Americann Inc
OTC:ACAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (18.6), the stock would be worth $-1.82 (1 817 706% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0 | $0 |
0%
|
| Industry Average | 18.6 | $-1.82 |
-1 817 706%
|
| Country Average | 22.9 | $-2.23 |
-2 231 146%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Americann Inc
OTC:ACAN
|
2.4k USD | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 42.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 26.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Americann Inc
Glance View
Americann, Inc. engages in the development and leasing of cannabis cultivation, processing and product manufacturing facilities. The company is headquartered in Denver, Colorado and currently employs 3 full-time employees. The company went IPO on 2013-09-10. The firm is developing product manufacturing and greenhouse cultivation facilities. Its flagship project is the Massachusetts Cannabis Center. The Massachusetts Cannabis Center (MCC) is being developed on an approximately 52-acre parcel located in Southeastern Massachusetts. Its MCC project is permitted for approximately 987,000 square feet of cannabis cultivation and processing infrastructure, which is being developed in phases to support both the existing medical cannabis and the newly emerging adult-use cannabis marketplace. Its first phase of the million square feet project, Building 1, is about 30,000 square feet. The firm through its subsidiary, AmeriCann Brands, Inc., has received two licenses from the Massachusetts Cannabis Control Commission to cultivate cannabis and provide extraction and product manufacturing support to the entire MCC project, as well as to other licensed cannabis farmers throughout regulated markets.
